By Fineline Cube Novo Nordisk A/S (NYSE: NVO) announced positive topline results from the Phase III HIBISCUS trial evaluating etavopivat, a once-daily oral pyruvate kinase-R (PKR) activator, in adult and adolescent patients with sickle cell disease (SCD). The study met both co-primary endpoints, showing statistically significant reductions in vaso-occlusive crises (VOCs) and improvement in hemoglobin (Hb) response versus placebo.
Trial Highlights
| Endpoint | Outcome |
|---|---|
| Vaso-Occlusive Crises (VOCs) | Significant reduction vs. placebo (p < 0.001) |
| Hemoglobin Response | Clinically meaningful Hb increase sustained over 24 weeks |
| Dosing | Once-daily oral tablet |
| Population | Adolescents (≥12 years) and adults with confirmed SCD |
| Safety | Consistent with prior studies; no new safety signals identified |
Mechanism of Action
- Target: Pyruvate kinase isoenzyme (PKR) in red blood cells (RBCs)
- Effect:
- ↓ 2,3-diphosphoglycerate (2,3-DPG) → reduces hemoglobin’s oxygen affinity
- ↑ Adenosine triphosphate (ATP) production → improves RBC health and deformability
- Outcome: Reduced sickling, hemolysis, and VOC frequency—addressing the root pathophysiology of SCD
Sickle cell disease affects an estimated 8 million people globally, with limited disease-modifying therapies available. Current standards include hydroxyurea, chronic transfusions, and newly approved gene therapies—many of which are invasive, costly, or inaccessible in low-resource regions.
Strategic & Commercial Implications
- Regulatory Timeline: Novo Nordisk plans to submit its first global regulatory application in H2 2026 (U.S. FDA and EMA anticipated)
- Differentiation: Etavopivat would be the first oral PKR activator approved for SCD, offering a non-gene-therapy, non-transfusion alternative
- Market Access: As a small-molecule pill, etavopivat could dramatically improve treatment accessibility in Africa, India, and other high-burden regions
- Portfolio Expansion: Marks Novo’s strategic entry into rare hematology, diversifying beyond its core diabetes and obesity franchises
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical outcomes, regulatory submissions, and commercial potential. Actual results may differ due to regulatory review timelines, competitive developments, and post-marketing safety data.-Fineline Info & Tech